KODIAK SCIENCES INC. Operating Lease, Payments
KODIAK SCIENCES INC. (KOD) reported Operating Lease, Payments of $16.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-31
- KODIAK SCIENCES INC. operating lease, payments for the quarter ending 2019-12-31 was $200.00K.
- KODIAK SCIENCES INC. operating lease, payments for the quarter ending 2019-09-30 was $100.00K.
- KODIAK SCIENCES INC. operating lease, payments for the quarter ending 2019-06-30 was $200.00K.
- KODIAK SCIENCES INC. operating lease, payments for the quarter ending 2019-03-31 was $100.00K.
- KODIAK SCIENCES INC. operating lease, payments for fiscal 2025 was $16.10M, a 1.77% increase from fiscal 2024.
- KODIAK SCIENCES INC. operating lease, payments for fiscal 2024 was $15.82M, a 4.40% increase from fiscal 2023.
- KODIAK SCIENCES INC. operating lease, payments for fiscal 2023 was $15.16M.
- KODIAK SCIENCES INC. operating lease, payments for fiscal 2019 was $600.00K.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $16.10M 10-K · filed 2026-03-31 | |||
| 2024-12-31 | $15.82M 10-K · filed 2026-03-31 | |||
| 2023-12-31 | $15.16M 10-K · filed 2026-03-31 | |||
| 2019-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $300.00K derived: sum of 2 quarters · filed 2020-03-16 | $500.00K derived: sum of 3 quarters · filed 2020-03-16 | $600.00K 10-K · filed 2020-03-16 |
| 2019-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $300.00K derived: sum of 2 quarters · filed 2019-11-12 | $400.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $300.00K 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $100.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |